Kerry Clem
Corporate Officer/Principal bei ACORDA THERAPEUTICS, INC.
Vermögen: 378 $ am 30.04.2024
Aktive Positionen von Kerry Clem
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACORDA THERAPEUTICS, INC. | Corporate Officer/Principal | 09.09.2021 | - |
Geschäftsführer | - | 09.09.2021 | |
Vertrieb & Marketing | 01.01.2011 | 09.09.2021 |
Karriereverlauf von Kerry Clem
Ehemalige bekannte Positionen von Kerry Clem
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Solstice Neurosciences, Inc.
Solstice Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Solstice Neurosciences, Inc. was a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. The company was founded in 2004 and is headquartered in Malvern, PA. | Vertrieb & Marketing | 01.01.2007 | 01.01.2010 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Vertrieb & Marketing | 01.01.2009 | 01.01.2010 |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Vertrieb & Marketing | - | - |
Ausbildung von Kerry Clem
Florida State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Sales & Marketing | 4 |
Undergraduate Degree | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ACORDA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Solstice Neurosciences, Inc.
Solstice Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Solstice Neurosciences, Inc. was a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products. The company was founded in 2004 and is headquartered in Malvern, PA. | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Börse
- Insiders
- Kerry Clem
- Erfahrung